According to Theravance Biopharma 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 7.6023. At the end of 2023 the company had a P/S ratio of 9.75.
Year | P/S ratio | Change |
---|---|---|
2023 | 9.75 | -33.78% |
2022 | 14.7 | -0.02% |
2021 | 14.7 | -7.45% |
2020 | 15.9 | -20.88% |
2019 | 20.1 | -14.81% |
2018 | 23.6 | -75.93% |
2017 | 98.1 | 188.12% |
2016 | 34.0 | 130.35% |
2015 | 14.8 | -64.07% |
2014 | 41.1 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
Corcept Therapeutics
CORT | 5.03 | -33.83% | ๐บ๐ธ USA |
Collegium Pharmaceutical
COLL | 2.12 | -72.14% | ๐บ๐ธ USA |
Catalyst Pharmaceuticals CPRX | 4.51 | -40.63% | ๐บ๐ธ USA |
Catalent CTLT | 2.49 | -67.30% | ๐บ๐ธ USA |